Advertisement

Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma

  • Zhitao Dong
  • Boyi Liao
  • Weifeng Shen
  • Chengjun Sui
  • Jiamei YangEmail author
Original Article
  • 22 Downloads

Abstract

Background

Programmed death ligand 1 (PD-L1) is expressed in many malignancies and plays a critical role in escape from immune surveillance through inhibition of its receptor programmed death 1. The role of PD-L1 in intrahepatic cholangiocarcinoma (ICC) and mechanisms of its regulation, however, remain largely unknown.

Aims

To analyze the expression and prognostic significance of PD-L1 in ICC and to study the regulatory mechanisms of PD-L1.

Methods

Samples were obtained from 125 patients diagnosed with ICC in the Eastern Hepatobiliary Surgery Hospital from January 2012 to January 2013. The records of each patient were analyzed to examine the relationship between PD-L1 and clinical data. In vitro experiments were performed to investigate the relationship between PD-L1 and the IL-6/mTOR signaling pathway and the feedback mechanism pathway of PD-L1.

Results

Expression of PD-L1 is closely related to tumor vascular invasion, lymphatic metastasis and TNM staging. High PD-L1 expression is closely related to poor prognosis in ICC. Mechanically, IL-6 induces PD-L1 expression through mTOR signaling in ICC cells. In addition, PD-L1 has a negative feedback inhibition effect on AKT signaling.

Conclusions

In summary, high PD-L1 expression was found to be associated with poor prognosis. The IL-6/mTOR pathway upregulates expression of PD-L1, thus promoting tumor invasion, and PD-L1 negatively inhibits the AKT pathway.

Keywords

Cholangiocarcinoma, bile duct Liver neoplasm B7-H1 antigen/CD274 protein, human Signal transduction Prognosis 

Notes

Acknowledgments

The authors thank Dr. Binghua Dai and Dr. Jiongjiong Lu for secretarial work.

Author’s contribution

ZD, BL: Conception and design, Development of methodology. CS, WS: Analysis and interpretation of data (e.g., statistical analysis). ZD: Writing, review, and/or revision of the manuscript. CS, WS: Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Chinchilla-Lopez P, Aguilar-Olivos NE, Garcia-Gomez J, et al. Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma. Ann Hepatol. 2017;16:565–568.  https://doi.org/10.5604/01.3001.0010.0293.CrossRefGoogle Scholar
  2. 2.
    Hogdall D, O’Rourke CJ, Taranta A, Oliveira DV, Andersen JB. Molecular pathogenesis and current therapy in intrahepatic cholangiocarcinoma. Dig Dis. 2016;34:440–451.  https://doi.org/10.1159/000444562.CrossRefGoogle Scholar
  3. 3.
    Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2018.  https://doi.org/10.1002/hep.30289.Google Scholar
  4. 4.
    Wang Y, Kim TH, Fouladdel S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep. 2019;9:566.  https://doi.org/10.1038/s41598-018-36096-7.CrossRefGoogle Scholar
  5. 5.
    Jiang C, Zhu Y, Tang S, et al. High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. Oncol Lett. 2019;17:1626–1634.  https://doi.org/10.3892/ol.2018.9747.Google Scholar
  6. 6.
    Han X, Gu YK, Li SL, et al. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. J Cancer Res Clin Oncol. 2019;145:303–312.  https://doi.org/10.1007/s00432-018-2758-6.CrossRefGoogle Scholar
  7. 7.
    Wu Y, Zhao T, Jia Z, et al. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer. J Gastroenterol Hepatol. 2018.  https://doi.org/10.1111/jgh.14520.Google Scholar
  8. 8.
    Wang X, Yang L, Huang F, et al. Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 2017;184:7–14.  https://doi.org/10.1016/j.imlet.2017.02.006.CrossRefGoogle Scholar
  9. 9.
    Moon JW, Kong SK, Kim BS, et al. IFNgamma induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. Sci Rep. 2017;7:17810.  https://doi.org/10.1038/s41598-017-18132-0.CrossRefGoogle Scholar
  10. 10.
    Tsukamoto H, Fujieda K, Miyashita A, et al. Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018.  https://doi.org/10.1158/0008-5472.can-18-0118.Google Scholar
  11. 11.
    Li J, Xu J, Yan X, Jin K, Li W, Zhang R. Targeting interleukin-6 (IL-6) sensitizes anti-PD-L1 treatment in a colorectal cancer preclinical model. Med Sci Monit. 2018;24:5501–5508.  https://doi.org/10.12659/MSM.907439.CrossRefGoogle Scholar
  12. 12.
    Xu L, Chen X, Shen M, et al. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Mol Oncol. 2017.  https://doi.org/10.1002/1878-0261.12135.Google Scholar
  13. 13.
    Rolvering C, Zimmer AD, Ginolhac A, et al. The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by alpha-PD-L1 or alpha-IL6 antibodies. J Leukoc Biol. 2018.  https://doi.org/10.1002/jlb.ma1217-495r.Google Scholar
  14. 14.
    Song X, Liu X, Wang H, et al. Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. Clin Cancer Res. 2019;25:403–413.  https://doi.org/10.1158/1078-0432.CCR-18-0284.CrossRefGoogle Scholar
  15. 15.
    O’Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. 2018;48:91–103.  https://doi.org/10.1016/j.semcancer.2017.04.015.CrossRefGoogle Scholar
  16. 16.
    Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018.  https://doi.org/10.1158/2326-6066.cir-17-0537.Google Scholar
  17. 17.
    Chen L, Xiong Y, Li J, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42:2267–2280.  https://doi.org/10.1159/000480000.CrossRefGoogle Scholar
  18. 18.
    Clark CA, Gupta HB, Sareddy G, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76:6964–6974.  https://doi.org/10.1158/0008-5472.CAN-16-0258.CrossRefGoogle Scholar
  19. 19.
    Kleffel S, Posch C, Barthel SR, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth S6. Cell. 2015;162:1242–1256.  https://doi.org/10.1016/j.cell.2015.08.052.CrossRefGoogle Scholar
  20. 20.
    Gao Y, Yang J, Cai Y, et al. IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018.  https://doi.org/10.1002/ijc.31357.Google Scholar
  21. 21.
    Chandrasekaran S, Sasaki M, Pollack BP. Interrogating PI3K to induce PD-L1 expression in oral carcinoma. J Clin Oncol. 2018.  https://doi.org/10.1200/jco.2018.36.15_suppl.e24119.Google Scholar
  22. 22.
    Derosa L, Routy B, Kroemer G, Zitvogel L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. Oncoimmunology. 2018;7:e1434468.  https://doi.org/10.1080/2162402X.2018.1434468.CrossRefGoogle Scholar
  23. 23.
    Maekawa N, Konnai S, Takagi S, et al. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Sci Rep. 2017;7:8951.  https://doi.org/10.1038/s41598-017-09444-2.CrossRefGoogle Scholar
  24. 24.
    Addeo R. A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). Expert Rev Anticancer Ther. 2017;17:199–201.  https://doi.org/10.1080/14737140.2017.1286986.CrossRefGoogle Scholar
  25. 25.
    Tremblay-LeMay R, Rastgoo N, Chang H. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. J Hematol Oncol. 2018;11:46.  https://doi.org/10.1186/s13045-018-0589-1.CrossRefGoogle Scholar
  26. 26.
    Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–452.  https://doi.org/10.1016/j.immuni.2018.03.014.CrossRefGoogle Scholar
  27. 27.
    LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 pathway in tumor therapy. J Immunol. 2018;200:375–383.  https://doi.org/10.4049/jimmunol.1701044.CrossRefGoogle Scholar
  28. 28.
    Zhu Y, Wang XY, Zhang Y, et al. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8(+) T-cell immune responses. Cancer Manag Res. 2018;10:4113–4123.  https://doi.org/10.2147/CMAR.S172719.CrossRefGoogle Scholar
  29. 29.
    Ueno T, Mitsuhashi T, Hatanaka Y, et al. Prognostic significance of PD-L1 expression in extrahepatic cholangiocarcinoma. Lab Investig. 2017;97:452A-A.Google Scholar
  30. 30.
    Pinno J, Bongartz H, Klepsch O, et al. Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner. Cell Signal. 2016;28:907–916.  https://doi.org/10.1016/j.cellsig.2016.04.004.CrossRefGoogle Scholar
  31. 31.
    Liu F, Zhang W, Yang F, et al. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep. 2016;6:21260.  https://doi.org/10.1038/srep21260.CrossRefGoogle Scholar
  32. 32.
    Kim HY, Jhun JY, Cho ML, et al. Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure. J Gastroenterol. 2014;49:1264–1273.  https://doi.org/10.1007/s00535-013-0891-1.CrossRefGoogle Scholar
  33. 33.
    Takada K, Toyokawa G, Tagawa T, et al. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer. 2018;116:1–6.  https://doi.org/10.1016/j.lungcan.2017.12.003.CrossRefGoogle Scholar
  34. 34.
    Qiu XY, Hu DX, Chen WQ, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1754–1769.  https://doi.org/10.1016/j.bbadis.2018.03.002.CrossRefGoogle Scholar
  35. 35.
    Park S, Cho S, Kim M, et al. Dermatofibrosarcoma protuberans: a retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression. J Am Acad Dermatol. 2018;79:843–852.  https://doi.org/10.1016/j.jaad.2018.05.016.CrossRefGoogle Scholar
  36. 36.
    Mou H, Yu L, Liao Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. BMC Cancer. 2018;18:1105.  https://doi.org/10.1186/s12885-018-5021-2.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Special Medical CareShanghai Eastern Hepatobiliary Surgery HospitalShanghaiChina

Personalised recommendations